Indian Journal of Pharmacy and Pharmacology

Print ISSN: 2393-9079

Online ISSN: 2393-9087

CODEN : IJPPTK

Indian Journal of Pharmacy and Pharmacology (IJPP) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award programs. With more...

Article type

Original Article


Article page

146-152


Authors Details

Ajay Kumar Halwai, Vinod Koshley*, Rajesh Hishikar, Basant Maheshwari, Usha Joshi


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 1419

PDF Downloaded: 591


Study of serum glucose and cholesterol level in schizophrenic patient’s before and after treatment of olanzapine, risperidone and haloperidol


Original Article

Author Details : Ajay Kumar Halwai, Vinod Koshley*, Rajesh Hishikar, Basant Maheshwari, Usha Joshi

Volume : 5, Issue : 3, Year : 2018

Article Page : 146-152

https://doi.org/10.18231/2393-9087.2018.0031



Suggest article by email

Get Permission

Abstract

Objectives: To evaluate the potential association between antipsychotics (Olanzapine, Risperidone and Haloperidol), serum glucose level and serum cholesterol level in schizophrenic patients.
Introduction: Schizophrenia is quite prevalent and has high rate of chronicity and morbidity. Newer atypical antipsychotic drugs were developed in response to limitations such as lack of efficacy and side effects associated with older (conventional) agents. However, significant hyperglycemia, dyslipidemia and weight gain have been reported with the use of newer atypical antipsychotics.
Materials and Methods: This was an observational prospective study. Total 75 schizophrenic patients were divided in three groups according to treatment allocated (group I- olanzapine, group II- risperidone, group III haloperidol) comprising of 25 patients in each group. Blood sample was collected when patient came to hospital for the first time before starting the treatment and 6 weeks after treatment, then again 6 months after treatment, fasting serum glucose and cholesterol levels were estimated by enzymatic procedure. Simultaneously body weight was also measured.
Results: In this study majority of patients were male-73.33% with mean age of 30.76 years. There were significant increase in serum glucose levels and serum cholesterol level, after 6 weeks and 6 months of treatment (t=3.11 p<0 xss=removed xss=removed> t=3.65 p < 0 t=3.11,> Conclusion: Olanzapine was associated with increased risk of glucose intolerance, dyslipidemia and weight gain.

Keywords: Antipsychotics, Schizophrenia, Cholesterol, Diabetes, Weight gain.


How to cite : Halwai A K, Koshley V, Hishikar R, Maheshwari B, Joshi U, Study of serum glucose and cholesterol level in schizophrenic patient’s before and after treatment of olanzapine, risperidone and haloperidol. Indian J Pharm Pharmacol 2018;5(3):146-152

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.